Compare PRSU & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSU | PCRX |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.6M | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | PRSU | PCRX |
|---|---|---|
| Price | $35.62 | $20.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $31.67 | ★ $35.33 |
| AVG Volume (30 Days) | 267.5K | ★ 1.1M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 902.95 | N/A |
| EPS | ★ 10.75 | 0.47 |
| Revenue | $441,143,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $26.24 | $6.21 |
| Revenue Next Year | $6.25 | $8.26 |
| P/E Ratio | ★ $3.51 | $43.88 |
| Revenue Growth | ★ 4.63 | 3.14 |
| 52 Week Low | $26.66 | $18.80 |
| 52 Week High | $41.72 | $27.64 |
| Indicator | PRSU | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 39.40 |
| Support Level | $34.05 | $19.94 |
| Resistance Level | $35.90 | $21.60 |
| Average True Range (ATR) | 1.13 | 0.95 |
| MACD | 0.13 | 0.12 |
| Stochastic Oscillator | 81.50 | 54.20 |
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.